CHMP says yes to developing world vaccine, Novartis' Seebri Breezhaler, Takeda's Revestive
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's scientific committee, the CHMP, has given the green light for the European Commission to OK a number of new medicines, including Takeda's orphan drug Revestive (teduglutide) for patients with short bowel syndrome. And, for the first time ever, it recommended a vaccine – Sanofi Pasteur's Hexaxim – for use in markets outside the EU.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.